Why the study?
Does dual antiplatelet therapy for 30 months reduce stent thrombosis and major adverse cardiovascular and cerebrovascular events in patients after placement of a drug-eluting stent?
Does dual antiplatelet therapy for 30 months reduce stent thrombosis and major adverse cardiovascular and cerebrovascular events in patients after placement of a drug-eluting stent?
Extending dual antiplatelet therapy to 30 months after drug-eluting stent placement reduces ischemic events and stent thrombosis but increases bleeding compared to standard 12-month therapy.
Extended DAPT post-DES may be considered in selected low-bleeding-risk patients; extends randomized evidence for ischemic benefit beyond 1 year.
Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
No takes yet. Share an insight, caveat, or question.
Mauri et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: